# SMPD3

## Overview
SMPD3 is a gene that encodes the enzyme sphingomyelin phosphodiesterase 3, also known as neutral sphingomyelinase 2 (nSMase2). This enzyme is a critical component of sphingolipid metabolism, primarily functioning within the Golgi apparatus to catalyze the hydrolysis of sphingomyelin into ceramide and phosphocholine. nSMase2 is a transmembrane protein characterized by distinct structural domains that facilitate its membrane association and catalytic activity. It plays a pivotal role in maintaining lipid balance, vesicular transport, and cellular stress responses. The enzyme is predominantly expressed in the brain and is involved in various cellular processes, including vesicle formation and protein transport, particularly in neurons and chondrocytes. Alterations in SMPD3 expression or function have been linked to several pathological conditions, including neurodegenerative diseases, muscular dystrophy, and bone development disorders, highlighting its clinical significance (Stoffel2018SMPD3; Stoffel2016Neutral; Matsuzaka2020The).

## Structure
The SMPD3 gene encodes the enzyme neutral sphingomyelinase 2 (nSMase2), which is a 655 amino acid protein with a molecular weight of 71 kDa. The protein is characterized by distinct structural domains that facilitate its function. The N-terminal domain includes a short juxtamembrane region and two hydrophobic segments that enable membrane association. This domain also contains two phosphatidylserine-binding sites, which are crucial for the enzyme's activation (Choezom2024Investigating).

The C-terminal catalytic domain of nSMase2 features a large insertion region with regulatory elements, including five phosphoserine sites and a calcineurin-binding site. The catalytic domain adopts a DNase-1-type fold, characterized by a β-sandwich core essential for Mg2+ ion binding and catalysis. This structural configuration is vital for the enzyme's role in ceramide production, which is important for various cellular processes (Choezom2024Investigating).

nSMase2 is primarily expressed in the brain and localizes to several subcellular compartments, including the plasma membrane, Golgi, endoplasmic reticulum, nucleus, and endosomes. Its localization and activity are influenced by different stimuli, such as TNFα and H2O2, highlighting its role in stress responses and cell cycle regulation (Choezom2024Investigating).

## Function
SMPD3, also known as sphingomyelin phosphodiesterase 3, is a crucial enzyme involved in sphingolipid metabolism, primarily active in the Golgi apparatus. It catalyzes the hydrolysis of sphingomyelin to produce ceramide and phosphocholine, playing a significant role in maintaining the balance of lipids such as sphingomyelin (SM), ceramide (Cer), and diacylglycerol (DAG) within the Golgi complex (Stoffel2016Neutral). This balance is essential for the formation and transport of vesicles, which are critical for the secretion of extracellular matrix proteins and proteo-hormones (Stoffel2016Neutral).

In healthy cells, SMPD3 is involved in the regulation of protein vesicular transport, which is vital for normal growth and development. Its activity is crucial for the Golgi secretory pathway, particularly in chondrocytes, where it helps prevent endoplasmic reticulum (ER) stress and apoptosis by ensuring proper protein transport (Stoffel2016Neutral). SMPD3 also plays a role in the central nervous system, where it is predominantly expressed in neurons. It is involved in the sphingomyelin cycle within the neuronal Golgi complex, which is important for lipid bilayer remodeling, vesicle formation, and protein transport (Stoffel2018SMPD3).

## Clinical Significance
Mutations or alterations in the expression of the SMPD3 gene, which encodes sphingomyelin phosphodiesterase 3, have been implicated in several diseases and conditions. In the central nervous system, SMPD3 deficiency is linked to neurodegenerative conditions resembling Alzheimer's disease. This deficiency leads to the accumulation of neurotoxic proteins such as amyloid precursor protein (APP), amyloid-beta (Aβ), and phosphorylated tau (pTau) in neurons, disrupting proteostasis and causing cognitive decline (Stoffel2018SMPD3). 

In muscular dystrophy, particularly in the mdx mouse model of Duchenne muscular dystrophy, the absence of SMPD3 reduces inflammation and muscle degeneration in early stages but increases muscle necrosis later. This suggests a complex role in modulating muscle pathology and stress responses (Matsuzaka2020The).

SMPD3 expression is also relevant in bone development and fracture healing. Its deficiency leads to delayed extracellular matrix mineralization and skeletal deformities, indicating its importance in bone health (Manickam2019Role). In gastric carcinoma, decreased SMPD3 expression is associated with advanced tumor stages, suggesting its potential as a diagnostic and prognostic biomarker (AbdelTawab2022Evaluation).

## Interactions
SMPD3, also known as neutral sphingomyelinase 2 (nSMase2), is involved in various protein interactions that are crucial for its function in cellular processes. In TNFα-stimulated Jurkat cells, nSMase2 forms a complex with proteins such as FAN, EED, and RACK1 within the first 5 minutes of stimulation, indicating its role in early signaling events (Schöl2024Dynamic). The proximity labeling technique identified approximately 5,500 proteins in the nSMase2 proximitome, with significant changes in protein interactions observed upon TNFα activation (Schöl2024Dynamic). 

nSMase2 is also associated with proteins involved in vesicle-mediated transport, including those related to recycling endosomes and exocytic vesicles, suggesting its involvement in membrane trafficking and exosome release (Schöl2024Dynamic). The enzyme's proximity to components of the multivesicular body (MVB) secretory machinery, such as Ras-related protein Rab-27A and vacuolar-sorting protein SNF8, highlights its role in vesicular transport and communication between organelles (Schöl2024Dynamic). 

These interactions underscore the importance of nSMase2 in modulating cellular responses to stress and inflammation, as well as its potential involvement in signaling pathways like MAPK and NFkB, although the phosphorylation of these pathways appears independent of nSMase2 activity in certain contexts (Schöl2024Dynamic).


## References


[1. (Stoffel2018SMPD3) Wilhelm Stoffel, Britta Jenke, Inga Schmidt-Soltau, Erika Binczek, Susanne Brodesser, and Ina Hammels. Smpd3 deficiency perturbs neuronal proteostasis and causes progressive cognitive impairment. Cell Death &amp; Disease, May 2018. URL: http://dx.doi.org/10.1038/s41419-018-0560-7, doi:10.1038/s41419-018-0560-7. This article has 20 citations.](https://doi.org/10.1038/s41419-018-0560-7)

[2. (Matsuzaka2020The) Yasunari Matsuzaka, Jun Tanihata, Yoshiko Ooshima, Daisuke Yamada, Masayuki Sekiguchi, Shouta Miyatake, Yoshitsugu Aoki, Mika Terumitsu, Ryu Yashiro, Hirofumi Komaki, Akihiko Ishiyama, Yasushi Oya, Yukiko U. Inoue, Takayoshi Inoue, Shin’ichi Takeda, and Kazuo Hashido. The nsmase2/smpd3 gene modulates the severity of muscular dystrophy and the emotional stress response in mdx mice. BMC Medicine, November 2020. URL: http://dx.doi.org/10.1186/s12916-020-01805-5, doi:10.1186/s12916-020-01805-5. This article has 12 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1186/s12916-020-01805-5)

[3. (AbdelTawab2022Evaluation) Marwa Sayed Abdel-Tawab, Hanan Fouad, Ahmed Yehia Ismaeel, Ahmed Abd-Eltawab Tammam, Alzhraa M. Fahmy, Saeed Shaaban, Soha Mahmoud Abdel-Salam, and Naglaa Adly Abd Elazeem. Evaluation of cep55, serpine1 and smpd3 genes and proteins as diagnostic and prognostic biomarkers in gastric carcinoma in egyptian patients. Beni-Suef University Journal of Basic and Applied Sciences, December 2022. URL: http://dx.doi.org/10.1186/s43088-022-00334-9, doi:10.1186/s43088-022-00334-9. This article has 1 citations.](https://doi.org/10.1186/s43088-022-00334-9)

[4. (Manickam2019Role) Garthiga Manickam, Pierre Moffatt, and Monzur Murshed. Role of smpd3 during bone fracture healing and regulation of its expression. Molecular and Cellular Biology, February 2019. URL: http://dx.doi.org/10.1128/mcb.00370-18, doi:10.1128/mcb.00370-18. This article has 12 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/mcb.00370-18)

5. (Choezom2024Investigating) Investigating the role of neutral sphingomyelinases in membrane vesicle trafficking. This article has 0 citations.

[6. (Schöl2024Dynamic) Marie Schöl, Rebekka Schempp, Thomas Hennig, Dominik Wigger, Fabian Schumacher, Burkhard Kleuser, Christian Stigloher, Marco van Ham, Lothar Jänsch, Sibylle Schneider-Schaulies, Lars Dölken, and Elita Avota. Dynamic changes in the proximitome of neutral sphingomyelinase-2 (nsmase2) in tnfα stimulated jurkat cells. Frontiers in Immunology, July 2024. URL: http://dx.doi.org/10.3389/fimmu.2024.1435701, doi:10.3389/fimmu.2024.1435701. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fimmu.2024.1435701)

[7. (Stoffel2016Neutral) Wilhelm Stoffel, Ina Hammels, Bitta Jenke, Erika Binczek, Inga Schmidt‐Soltau, Susanne Brodesser, Astrid Schauss, Julia Etich, Juliane Heilig, and Frank Zaucke. Neutral sphingomyelinase (smpd3) deficiency disrupts the golgi secretory pathway and causes growth inhibition. Cell Death &amp; Disease, 7(11):e2488–e2488, November 2016. URL: http://dx.doi.org/10.1038/cddis.2016.385, doi:10.1038/cddis.2016.385. This article has 38 citations.](https://doi.org/10.1038/cddis.2016.385)